Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Seock–Ah –A Im"'
Autor:
Sylvie Le Mouhaer, Mark Clemons, Walter Jonat, Laurence Bourdeau, Barbara Pistilli, Javier Cortes, Carlos L. Arteaga, Dalila Sellami, Banu Sankaran, Yoshinori Ito, Sara A. Hurvitz, Ling Min Tseng, Seock–Ah –A Im, Ahmad Awada, José Baselga, Mona El-Hashimy, Stephen Chia, Zefei Jiang, Mario Campone, Agnieszka Jagiełło-Gruszfeld, Norikazu Masuda, Hiroji Iwata, Michele De Laurentiis
Publikováno v:
European Journal of Cancer. 103:147-154
Background Buparlisib, a pan-phosphatidylinositol 3-kinase (PI3K) inhibitor, plus fulvestrant in the BELLE-2 study significantly improved progression-free survival (PFS) in patients with hormone receptor-positive, human epidermal growth factor recept
Autor:
Joon Jeong, Soo Jung Lee, Seok J. Nam, Eun Seong Lee, Hyun Kim, Se H. Cho, Seon-Ok Kim, Sung S. Kang, Sung Y. Kim, Wonshik Han, Kyong Hwa Park, Sei H. Ahn, Seock–Ah –A Im, Se Hwan Han, Jung H. Yoon, Hee J. Kim, Min H. Hur, Yong S. Jung, Byeong Woo Park, Min H. Lee, Woo C. Noh
Publikováno v:
European journal of cancer (Oxford, England : 1990). 151
Adding ovarian function suppression (OFS) after chemotherapy improves survival in young women with moderate- and high-risk breast cancer. Assessment of ovarian function restoration after chemotherapy becomes critical for subsequent endocrine treatmen
Autor:
Carlos L. Arteaga, Mark Clemons, Soulef Hachemi, Barbara Pistilli, Javier Cortes, José Baselga, Zefei Jiang, Norikazu Masuda, Agnieszka Jagiełło-Gruszfeld, Bharani Dharan, Seock–Ah –A Im, Masato Takahashi, Patrick Urban, Peter Vuylsteke, Ling Ming Tseng, Hiroji Iwata, Mario Campone, Walter Jonat, Yoshinori Ito, Sara A. Hurvitz, Ahmad Awada, Michele De Laurentiis, Cristian Massacesi, Stephen Chia, Emmanuelle di Tomaso
Publikováno v:
Repositorio Institucional de la Consejería de Sanidad de la Comunidad de Madrid
Consejería de Sanidad de la Comunidad de Madrid
The Lancet. Oncology, vol 18, iss 7
Consejería de Sanidad de la Comunidad de Madrid
The Lancet. Oncology, vol 18, iss 7
BackgroundPhosphatidylinositol 3-kinase (PI3K) pathway activation is a hallmark of endocrine therapy-resistant, hormone receptor-positive breast cancer. This phase 3 study assessed the efficacy of the pan-PI3K inhibitor buparlisib plus fulvestrant in
Autor:
Audrey Mailliez, Denise A. Yardley, Mary Tagliaferri, David Potter, Alison L. Hannah, Jin Seok Ahn, Edith A. Perez, Alvaro Moreno-Aspitia, Javier Cortes, Ute Hoch, Hope S. Rugo, Chris Twelves, Ahmad Awada, Seock–Ah –A Im, Patricia Gómez-Pardo, Lee S. Schwartzberg, Joyce O'Shaughnessy, Carol Zhao, Véronique Diéras
Publikováno v:
Breast cancer research and treatment, vol 165, iss 2
Repositorio Institucional de la Consejería de Sanidad de la Comunidad de Madrid
Consejería de Sanidad de la Comunidad de Madrid
Breast cancer research and treatment, 165 (2
Breast Cancer Research and Treatment
Repositorio Institucional de la Consejería de Sanidad de la Comunidad de Madrid
Consejería de Sanidad de la Comunidad de Madrid
Breast cancer research and treatment, 165 (2
Breast Cancer Research and Treatment
Purpose: Conventional chemotherapy has limited activity in patients with breast cancer and brain metastases (BCBM). Etirinotecan pegol (EP), a novel long-acting topoisomerase-1 inhibitor, was designed using advanced polymer technology to preferential
Autor:
Sherwin K. B. Sy, Deborah D.A. Zajchowski, Ahmad Awada, Javier Cortes, Seock–Ah –A Im, Ute Hoch, Edith A. Perez, Darren W. Davis, Mary Tagliaferri, Lin Lu, Hope S. Rugo, Joyce O'Shaughnessy, Alison L. Hannah, Chris Twelves, Katie Caygill
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 24(14)
Purpose: Preplanned exploratory analyses were performed to identify biomarkers in circulating tumor cells (CTC) predictive of response to the topoisomerase 1 inhibitor etirinotecan pegol (EP). Experimental Design: The BEACON trial treated patients wi
Autor:
Javier Cortes, Alison L. Hannah, Mary Tagliaferri, Hope S. Rugo, Ahmad Awada, David Potter, Chris Twelves, Edith A. Perez, Carol Zhao, Jin Seok Ahn, Ute Hoch, Patricia Gómez-Pardo, Seock–Ah –A Im, Audrey Mailliez, Lee S. Schwartzberg, Joyce O'Shaughnessy, Véronique Diéras, Denise A. Yardley, Alvaro Moreno-Aspitia
Publikováno v:
European journal of cancer, 76
Background Health-related quality of life (HRQoL) enhances understanding of treatment effects that impact clinical decision-making. Although the primary end-point was not achieved, the BEACON (BrEAst Cancer Outcomes with NKTR-102) trial established e
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::075495c4b94b1b2be2699af940cd153b
https://eprints.whiterose.ac.uk/114408/1/1-s2.0-S0959804917307360-main.pdf
https://eprints.whiterose.ac.uk/114408/1/1-s2.0-S0959804917307360-main.pdf
Autor:
Mary Tagliaferri, Edith A. Perez, Ahmad Awada, Audrey Mailliez, Véronique Diéras, Denise A. Yardley, Patricia Gómez-Pardo, Javier Cortes, Alison L. Hannah, Lee S. Schwartzberg, Joyce O'Shaughnessy, Hope S. Rugo, Carol Zhao, David Potter, Jin Seok Ahn, Chris Twelves, Alvaro Moreno-Aspitia, Seock–Ah –A Im, Ute Hoch
Conventional chemotherapy has limited activity in patients with breast cancer and brain metastases (BCBM). Etirinotecan pegol (EP), a novel long-acting topoisomerase-1 inhibitor, was designed using advanced polymer technology to preferentially accumu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::53a15b55c3fc4e06b96bc7a584d3136c
https://europepmc.org/articles/PMC6828475/
https://europepmc.org/articles/PMC6828475/
Autor:
Ute Hoch, Alison L. Hannah, Ahmad Awada, Seock–Ah –A Im, Carol Zhao, Javier Cortes, Hope S. Rugo, Denise Tomkinson, Joyce O'Shaughnessy, Edith A. Perez, Chris Twelves, James Buchanan, Mary Tagliaferri
Publikováno v:
Repositorio Institucional de la Consejería de Sanidad de la Comunidad de Madrid
Consejería de Sanidad de la Comunidad de Madrid
SpringerPlus, 5 (1
SpringerPlus, vol 5, iss 1
SpringerPlus
Consejería de Sanidad de la Comunidad de Madrid
SpringerPlus, 5 (1
SpringerPlus, vol 5, iss 1
SpringerPlus
Purpose: New treatments with novel mechanisms of action and non-overlapping toxicities are needed for patients with metastatic breast cancer. Etirinotecan pegol (EP) is a long-acting topoisomerase-I inhibitor with a unique toxicity profile. The rando
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d3699daad9c34120270e4bcc927113ba
Autor:
Denise A. Yardley, Seock–Ah –A Im, Jin Seok Ahn, Edith A. Perez, Mary Tagliaferri, Alison L. Hannah, Chris Twelves, Javier Cortes, Ute Hoch, Audrey Mailliez, Patricia Gómez-Pardo, Ahmad Awada, Hope S. Rugo, David Potter, Lee S. Schwartzberg, Joyce O'Shaughnessy, Carol Zhao, Alvaro Moreno-Aspitia, Véronique Diéras
Publikováno v:
The Lancet. Oncology. 16(15)
New options are needed for patients with heavily pretreated breast cancer. Etirinotecan pegol is a long-acting topoisomerase-I inhibitor that prolongs exposure to, but reduces the toxicity of, SN38 (the active metabolite of irinotecan). We assessed w